middle.news
Noxopharm’s Sofra Platform Amplifies TLR8 Immune Response Over 200-Fold
8:21am on Tuesday 26th of May, 2026 AEST
•
Biotechnology
Read Story
Noxopharm’s Sofra Platform Amplifies TLR8 Immune Response Over 200-Fold
8:21am on Tuesday 26th of May, 2026 AEST
Key Points
Sofra oligonucleotides amplify TLR8 activity 200-fold in human tissue
Animal models show nearly 3-fold immune response increase
US patent protection supports competitive positioning
Immuno-oncology market projected to reach US$185 billion by 2035
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Noxopharm (ASX:NOX)
OPEN ARTICLE